Richard Markus's most recent trade in Arcus Biosciences Inc was a trade of 96,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 23, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcus Biosciences Inc | Richard Markus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2026 | 96,000 | 96,000 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Richard Markus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2026 | 24,000 | 89,647 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Richard Markus | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.88 per share. | 16 Dec 2025 | 5,052 | 70,141 (0%) | 0% | 21.9 | 110,559 | Common Stock |
| Arcus Biosciences Inc | Richard Markus | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.16 per share. | 16 Dec 2025 | 4,494 | 65,647 (0%) | 0% | 22.2 | 99,585 | Common Stock |
| Arcus Biosciences Inc | Richard Markus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 305,328 | 305,328 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Richard Markus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 75,193 | 75,193 (0%) | 0% | 0 | Common Stock |